Market Overview

Bristol-Myers Looks To A Promising Future

Bristol-Myers Looks To A Promising Future

Pharmaceutical company Bristol-Myers Squibb Co (NYSE: BMY) has some big opportunities on the horizon, and analysts are taking notice.

At a time when many pharma companies are beginning to worry about political battles over lowering drug prices, Bristol-Myers Squibb is hoping its bright future will outweigh any negativity coming from Washington, as the company's cancer fighting drug Opdivo is set to become a major player in the cancer-treatment space throughout the coming years, according to Barron's.


Opdivo is an immuno-oncology drug that has been successful in blocking patients' T-cell receptors and helping their immune systems detect cancerous cells and attack them. Currently, Opdivo is the most successful immuno-oncology drug on the market and has been approved for use against three different types of cancer. Opdivo was also the subject of Bristol-Myers' latest ad campaign, as the firm looked to broaden patient interest in the drug.

Related Link: Barron's Picks And Pans: Bristol-Myers Squibb, KeyCorp, Core-Mark And More

Immuno-Oncology Shows Promise

Drugs that treat very specific illnesses or affect only a small segment of the population have become lucrative ways for drug companies to maintain their profits as more and more generic brands are created. At the moment, Bristol-Myers' Opdivo costs around $12,500 per month as there are no generic brands, making it a huge money maker for the company.

Pharma Sector Under Political Weight

With such a promising future ahead, many are questioning why shares of Bristol-Myers are down nearly 10 percent so far this year.

The pharmaceutical industry has declined on a whole this year, as the upcoming election has weighed on investor sentiment. Rising prescription drug prices have been a huge topic in this year's presidential campaigns, and many worry that the pharma sector will suffer once a new administration takes over.

Image Credit: Public Domain

Posted-In: Biotech Long Ideas Health Care Politics Top Stories Markets Trading Ideas General Best of Benzinga


Related Articles (BMY)

View Comments and Join the Discussion!

Staples Sells Its Commercial Contracts And Assets To Essendant

Maybe Another Buying Opportunity With Gold ETFs